Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9710MR)

This product GTTS-WQ9710MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9710MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5475MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ15627MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ13869MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ10890MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ2224MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ7323MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ10312MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ4694MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW